Barclays’s Lexicon Pharmaceuticals LXRX Stock Holding History

Barclays’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,000	Closed	-$2K	–	5973
2020 Q1	$2K	Hold	1,000	–	–	﹤0.01%	6028
2019 Q4	$4K	Sell	1,000 -700	-41%	-$2.69K	﹤0.01%	6191
2019 Q3	$5K	Buy	1,700 +1,000	+143%	+$3.1K	﹤0.01%	6448
2019 Q2	$4K	Sell	700 -3,500	-83%	-$21K	﹤0.01%	6726
2019 Q1	$23K	Buy	4,200 +3,900	+1,300%	+$23.7K	﹤0.01%	6298
2018 Q4	$2K	Hold	300	–	–	﹤0.01%	6721
2018 Q3	$3K	Sell	300 -1,000	-77%	-$11.5K	﹤0.01%	6892
2018 Q2	$16K	Hold	1,300	–	–	﹤0.01%	6300
2018 Q1	$11K	Buy	1,300 +600	+86%	+$5.55K	﹤0.01%	6634
2017 Q4	$7K	Hold	700	–	–	﹤0.01%	6598
2017 Q3	$9K	Sell	700 -35,300	-98%	-$521K	﹤0.01%	6175
2017 Q2	$593K	Buy	+36,000	New	+$557K	﹤0.01%	3355
2017 Q1	–	Sell	-400	Closed	-$6K	–	6882
2016 Q4	$6K	Buy	+400	New	+$6.42K	﹤0.01%	6080
2016 Q1	–	Sell	-65,800	Closed	-$855K	–	6308
2015 Q4	$855K	Buy	+65,800	New	+$809K	﹤0.01%	2753

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Barclays's LXRX Position: Q1 2026 in Review

Barclays reduced its Lexicon Pharmaceuticals (LXRX) stake by 46% in Q1 2026, selling an estimated $130K and leaving 105,487 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #3805.

Barclays first reported a position in LXRX in Q2 2013 and has held it in 52 quarters since. The position peaked at $907K in Q2 2016. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

Barclays held 105,487 shares of Lexicon Pharmaceuticals worth $165K as of Q1 2026.
Barclays sold 89,256 Lexicon Pharmaceuticals shares in Q1 2026, an estimated $130K.
Lexicon Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3805 holding.
Barclays first reported a position in Lexicon Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
Barclays's Lexicon Pharmaceuticals position peaked at $907K in Q2 2016.
136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.